In Memoriam - June 10, 1954 - March 15, 2021

When Eileen Youtie was diagnosed with breast cancer in December 2013, she accepted not only the challenge to fight for herself, but the opportunity to help others by raising awareness about hereditary cancers.

Eileen’s cancer was traced to a BRCA gene, a genetic mutation that greatly increases a woman’s risk of developing breast or ovarian cancer. Hereditary mutations of the BRCA gene are far more prevalent in people of Ashkenazi Jewish descent, like Eileen, than in the general population — about one in 40 compared with one in 500. Believing that the course of her cancer may have been different if she had been aware of her increased risk, Eileen became a passionate and vocal advocate of early screening and genetic testing.

Eileen was a dedicated member of the board of directors of Yodeah (“to know” in Hebrew), an outreach organization dedicated to educating people about the BRCA gene and facilitating cost-effective testing to save lives through prevention and early detection. Yodeah has since joined forces with Sophia George, Ph.D., at Sylvester, whose research studies the BRCA mutations that are prevalent among Caribbean women. Together, Yodeah and Dr. George are working to spread awareness of preventive strategies for reducing breast and ovarian cancers in the community at large.

Vivacious and upbeat, Eileen also channeled her considerable energy into survivorship work and involvement with women’s cancer groups. Even as she continued to fight her own cancer, she mentored other patients, helping them to navigate the ups and downs associated with their treatment.

Throughout her journey, Eileen was supported by her loving family, formed deep connections with other cancer survivors, and enjoyed a special camaraderie with her doctors. Fittingly, she crossed the DCC X finish line with her sister, one of her friends who is also a cancer survivor, and Carmen J. Calfa, M.D., of Sylvester, whom Eileen knew since her initial diagnosis.

"You have to focus on making every moment of your life count," Eileen said. "If you have purpose, it gets you through so much."

"Eileen, our beloved wife and mother, was a superhero in all aspects of her life and a trailblazer in raising awareness for BRCA gene mutations in the Ashkenazi Jewish community. She wholeheartedly believed that she was diagnosed with cancer, persevered through eight years of agonizing chemotherapy and other treatments, and was ultimately put on this Earth to help others by telling her story and encouraging people to get tested for BRCA. This led her to saving hundreds of lives and we plan to honor her legacy by living every day to its fullest, continuing her work with Yodeah, and raising awareness for hereditary cancers. We love her and miss her every day and although she is no longer physically here with us, her unparalleled love and strength persevere."

With eternal love, Phil, Haleigh and Max Youtie

There’s nothing like the doctors at Sylvester. No one cares as much, tries harder to find treatments that will work for you, or gives you as much hope and positive reinforcement.
The critical funding that I receive from the DCC has allowed me to delve into the science behind the important cancer disparities within the Black Caribbean population. The next step is to take the information into the community, where the science can make a lasting impact.

Sophia George, Ph.D.
Research Associate Professor, Obstetrics, Gynecology & Reproductive Science
Sylvester Comprehensive Cancer Center
University of Miami Miller School of Medicine

Dcc Impact

Sylvester offers patients like Eileen both genomic sequencing — testing of DNA from tumors to identify cancer-promoting genetic mutations — and therapy options and clinical trials that target those specific mutations. The philanthropic support of the DCC is vital in helping to bring these precision medicine clinical trials to Sylvester. 

About 15 to 20 percent of breast cancer diagnoses are currently attributed to genetic mutations, most commonly in the BRCA1 or BRCA2 gene. When these alterations are identified through testing, it can help to determine a patient’s eligibility for precision medicine clinical trials and potentially change the course of their disease. 

Generally designed for patients who have exhausted other, more conventional forms of treatment, these trials treat each cancer according to its unique genetic markers, allowing for individualized care that is more precise and less toxic, and that often produce better and longer-lasting results. 

Dr. George’s laboratory work focuses on BRCA gene mutations linked to aggressive breast and ovarian cancers in Caribbean women, using fallopian tube epithelial cells to study early genomic changes that lead to cancer. Her precision prevention research has received direct funding from the DCC for two consecutive years, and will translate to saving many lives by educating women in this high-risk category about preventative cancer treatment options such as bilateral salpingectomy (removal of both fallopian tubes) and oophorectomy (removal of the ovaries).

Share this story
Fundraising support from the DCC is significant in allowing us opportunities to start off breakthrough research from the ground up.

Carmen J. Calfa, M.D.
Medical Oncologist, Breast Cancer
Sylvester Comprehensive Cancer Center
Dr. Calfa participates every year in the DCC with her patients, family and friends.